JP7316261B2 - 骨髄異形成症候群の治療方法 - Google Patents

骨髄異形成症候群の治療方法 Download PDF

Info

Publication number
JP7316261B2
JP7316261B2 JP2020504178A JP2020504178A JP7316261B2 JP 7316261 B2 JP7316261 B2 JP 7316261B2 JP 2020504178 A JP2020504178 A JP 2020504178A JP 2020504178 A JP2020504178 A JP 2020504178A JP 7316261 B2 JP7316261 B2 JP 7316261B2
Authority
JP
Japan
Prior art keywords
composition
subject
imetelstat
mds
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020504178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528915A5 (enExample
JP2020528915A (ja
Inventor
アレクサンドラ リゾ，
ジャクリーン シリーロ ブッソラリ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7316261(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Geron Corp filed Critical Geron Corp
Publication of JP2020528915A publication Critical patent/JP2020528915A/ja
Publication of JP2020528915A5 publication Critical patent/JP2020528915A5/ja
Priority to JP2022183229A priority Critical patent/JP7654615B2/ja
Application granted granted Critical
Publication of JP7316261B2 publication Critical patent/JP7316261B2/ja
Priority to JP2023197448A priority patent/JP7654761B2/ja
Priority to JP2024197684A priority patent/JP2025013669A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020504178A 2017-07-28 2018-07-27 骨髄異形成症候群の治療方法 Active JP7316261B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022183229A JP7654615B2 (ja) 2017-07-28 2022-11-16 骨髄異形成症候群の治療方法
JP2023197448A JP7654761B2 (ja) 2017-07-28 2023-11-21 骨髄異形成症候群の治療方法
JP2024197684A JP2025013669A (ja) 2017-07-28 2024-11-12 骨髄異形成症候群の治療方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762538315P 2017-07-28 2017-07-28
US62/538,315 2017-07-28
US201762595329P 2017-12-06 2017-12-06
US62/595,329 2017-12-06
US201862685542P 2018-06-15 2018-06-15
US62/685,542 2018-06-15
PCT/US2018/044225 WO2019023667A1 (en) 2017-07-28 2018-07-27 METHODS OF TREATING MYELODYSPLASTIC SYNDROME

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022183229A Division JP7654615B2 (ja) 2017-07-28 2022-11-16 骨髄異形成症候群の治療方法

Publications (3)

Publication Number Publication Date
JP2020528915A JP2020528915A (ja) 2020-10-01
JP2020528915A5 JP2020528915A5 (enExample) 2021-09-02
JP7316261B2 true JP7316261B2 (ja) 2023-07-27

Family

ID=63209674

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020504178A Active JP7316261B2 (ja) 2017-07-28 2018-07-27 骨髄異形成症候群の治療方法
JP2022183229A Active JP7654615B2 (ja) 2017-07-28 2022-11-16 骨髄異形成症候群の治療方法
JP2023197448A Active JP7654761B2 (ja) 2017-07-28 2023-11-21 骨髄異形成症候群の治療方法
JP2024197684A Pending JP2025013669A (ja) 2017-07-28 2024-11-12 骨髄異形成症候群の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022183229A Active JP7654615B2 (ja) 2017-07-28 2022-11-16 骨髄異形成症候群の治療方法
JP2023197448A Active JP7654761B2 (ja) 2017-07-28 2023-11-21 骨髄異形成症候群の治療方法
JP2024197684A Pending JP2025013669A (ja) 2017-07-28 2024-11-12 骨髄異形成症候群の治療方法

Country Status (17)

Country Link
US (1) US12171778B2 (enExample)
EP (1) EP3658156A1 (enExample)
JP (4) JP7316261B2 (enExample)
KR (2) KR102867725B1 (enExample)
CN (1) CN110944646A (enExample)
AU (2) AU2018307983B2 (enExample)
BR (1) BR112020001749A2 (enExample)
CA (1) CA3069010A1 (enExample)
CL (2) CL2020000196A1 (enExample)
IL (1) IL272163B1 (enExample)
MA (1) MA49688A (enExample)
MX (1) MX2025005894A (enExample)
SG (1) SG11201913984RA (enExample)
TW (1) TWI879717B (enExample)
UA (1) UA127701C2 (enExample)
WO (1) WO2019023667A1 (enExample)
ZA (1) ZA202000070B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TWI879717B (zh) 2017-07-28 2025-04-11 美商傑龍公司 治療骨髓增生不良症候群之方法
SG11202105573PA (en) 2018-11-29 2021-06-29 Geron Corp Methods of treating myelodysplastic syndrome
CN115776909A (zh) 2020-07-17 2023-03-10 美国杰龙生物医药公司 皮下端粒酶抑制剂组合物及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504307A (ja) 2012-12-07 2016-02-12 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2016537423A (ja) 2013-11-06 2016-12-01 アヤルー テフェリ 血液悪性腫瘍を処置するための方法および材料

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
WO2001053307A1 (en) 2000-01-21 2001-07-26 Geron Corporation 2'-arabino-fluorooligonucleotide n3'→p5'phosphoramidates: their synthesis and use
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
WO2002077184A2 (en) 2001-03-23 2002-10-03 Geron Corporation Oligonucleotide conjugates
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
JP4690324B2 (ja) 2003-09-09 2011-06-01 ジェロン・コーポレーション テロメラーゼ阻害のための改変オリゴヌクレオチド
AU2004289975B2 (en) 2003-11-04 2011-11-03 Geron Corporation RNA amidates and thioamidates for RNAI
US20050282893A1 (en) 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
RS56361B1 (sr) 2004-07-02 2017-12-29 Geron Corp Sinteza zaštićenih 3'-amino nukleozidnih monomera
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
EP1910342A1 (en) 2005-07-29 2008-04-16 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US8153604B2 (en) 2006-04-24 2012-04-10 Geron Corporation CNS-tumor treatment method and composition
PL2101789T3 (pl) 2006-10-30 2015-05-29 Geron Corp Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9155753B2 (en) 2007-03-09 2015-10-13 Geron Corporation Treatment of carcinomas with a combination of EGF-pathway and telomerase inhibitors
US8367078B2 (en) 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
CN101220044B (zh) 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8227202B2 (en) 2008-07-10 2012-07-24 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
PT3029154T (pt) 2008-10-17 2017-12-06 Geron Corp Método para identificação de sensibilidade de um paciente à terapia de inibição da telomerase
US8772264B2 (en) 2009-08-04 2014-07-08 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
EP2534261B1 (en) 2010-02-12 2016-11-30 QIAGEN Marseille Asxl1 as a new diagnostic marker of myeloid neoplasms
US8460872B2 (en) 2011-04-29 2013-06-11 Sequenom, Inc. Quantification of a minority nucleic acid species
WO2013056211A2 (en) 2011-10-13 2013-04-18 H. Lee Moffitt Cancer Center & Research Institute, Inc. Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome
EP2771010A4 (en) 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS
US9593137B2 (en) 2011-12-22 2017-03-14 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
ES2972330T3 (es) 2012-11-30 2024-06-12 Geron Corp Marcadores diagnósticos para el tratamiento de trastornos proliferativos celulares con inhibidores de la telomerasa
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20160022708A1 (en) 2013-03-14 2016-01-28 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
EP3318276A1 (en) 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
TWI879717B (zh) 2017-07-28 2025-04-11 美商傑龍公司 治療骨髓增生不良症候群之方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016504307A (ja) 2012-12-07 2016-02-12 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
JP2016537423A (ja) 2013-11-06 2016-12-01 アヤルー テフェリ 血液悪性腫瘍を処置するための方法および材料

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Blood Cancer Journal, 2016, Vol.6, #e405
Blood, 2017.12, Vol.130, No.Suppl.1, p.4256, #637
Leukemia Research, 2017（2016.11 available online), Vol.52, pp.50-57
Oncotarget, 2017.2, Vol.8, No.23, pp.37866-37874
Study NCT01731951 on Date: June 16, 2017 (v14)，ClinicalTrials.gov archive[online]，2017年6月16日，[2022年7月19日検索]，<URL: https://clinicaltrials.gov/ct2/history/NCT01731951>

Also Published As

Publication number Publication date
KR20200033269A (ko) 2020-03-27
TWI879717B (zh) 2025-04-11
NZ760873A (en) 2024-03-22
KR102867725B1 (ko) 2025-10-13
EP3658156A1 (en) 2020-06-03
CL2021001096A1 (es) 2021-11-12
JP7654761B2 (ja) 2025-04-01
TW201919705A (zh) 2019-06-01
JP7654615B2 (ja) 2025-04-01
JP2024015000A (ja) 2024-02-01
US20190030064A1 (en) 2019-01-31
JP2020528915A (ja) 2020-10-01
AU2018307983B2 (en) 2024-07-18
JP2025013669A (ja) 2025-01-24
IL272163A (en) 2020-03-31
CL2020000196A1 (es) 2020-11-20
UA127701C2 (uk) 2023-12-06
CA3069010A1 (en) 2019-01-31
JP2023009229A (ja) 2023-01-19
AU2018307983A1 (en) 2020-02-13
MA49688A (fr) 2020-06-03
AU2024219941A1 (en) 2024-10-10
TW202432146A (zh) 2024-08-16
CN110944646A (zh) 2020-03-31
KR20250151565A (ko) 2025-10-21
MX2025005894A (es) 2025-06-02
IL272163B1 (en) 2025-12-01
WO2019023667A1 (en) 2019-01-31
US12171778B2 (en) 2024-12-24
SG11201913984RA (en) 2020-02-27
ZA202000070B (en) 2025-09-25
BR112020001749A2 (pt) 2020-07-21

Similar Documents

Publication Publication Date Title
JP7654761B2 (ja) 骨髄異形成症候群の治療方法
KR102515378B1 (ko) 혈액 암을 위한 조합 치료법
US20250170160A1 (en) Methods of Treating Myelodysplastic Syndrome
TWI906757B (zh) 治療骨髓增生不良症候群之方法
HK40027129A (en) Methods of treating myelodysplastic syndrome
EA050072B1 (ru) Способы лечения миелодиспластического синдрома
EA045910B1 (ru) Способы лечения миелодиспластического синдрома
EA043524B1 (ru) Способы лечения миелодиспластического синдрома
HK40063245A (en) Methods of treating myelodysplastic syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230714

R150 Certificate of patent or registration of utility model

Ref document number: 7316261

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157